State Street’s Collegium Pharmaceutical COLL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$47.1M Buy
1,424,544
+113,903
+9% +$4.82M ﹤0.01% 1771
2025
Q4
$60.7M Buy
1,310,641
+16,730
+1% +$700K ﹤0.01% 1636
2025
Q3
$45.3M Sell
1,293,911
-60,506
-4% -$2.1M ﹤0.01% 1774
2025
Q2
$40.1M Sell
1,354,417
-20,588
-1% -$587K ﹤0.01% 1795
2025
Q1
$41M Sell
1,375,005
-62,149
-4% -$1.9M ﹤0.01% 1743
2024
Q4
$41.2M Buy
1,437,154
+63,828
+5% +$2.11M ﹤0.01% 1822
2024
Q3
$53.1M Sell
1,373,326
-6,627
-0.5% -$236K ﹤0.01% 1681
2024
Q2
$44.4M Buy
1,379,953
+60,898
+5% +$2.11M ﹤0.01% 1730
2024
Q1
$51.2M Buy
1,319,055
+5,180
+0.4% +$181K ﹤0.01% 1717
2023
Q4
$40.4M Buy
1,313,875
+23,379
+2% +$586K ﹤0.01% 1824
2023
Q3
$28.8M Buy
1,290,496
+23,027
+2% +$525K ﹤0.01% 1942
2023
Q2
$27.2M Sell
1,267,469
-85,223
-6% -$1.93M ﹤0.01% 2044
2023
Q1
$32.5M Buy
1,352,692
+64,478
+5% +$1.71M ﹤0.01% 1917
2022
Q4
$29.9M Sell
1,288,214
-74,448
-5% -$1.5M ﹤0.01% 1966
2022
Q3
$21.8M Sell
1,362,662
-28,031
-2% -$494K ﹤0.01% 2155
2022
Q2
$24.6M Buy
1,390,693
+82,526
+6% +$1.39M ﹤0.01% 2102
2022
Q1
$26.6M Buy
1,308,167
+165,144
+14% +$3.12M ﹤0.01% 2186
2021
Q4
$21.4M Sell
1,143,023
-8,639
-0.8% -$168K ﹤0.01% 2436
2021
Q3
$22.7M Sell
1,151,662
-2,761
-0.2% -$59.7K ﹤0.01% 2387
2021
Q2
$27.3M Buy
1,154,423
+58,221
+5% +$1.34M ﹤0.01% 2309
2021
Q1
$26M Buy
1,096,202
+332,734
+44% +$7.9M ﹤0.01% 2195
2020
Q4
$15.3M Buy
763,468
+10,907
+1% +$213K ﹤0.01% 2393
2020
Q3
$15.7M Sell
752,561
-62,582
-8% -$1.13M ﹤0.01% 2173
2020
Q2
$14.3M Buy
815,143
+105,337
+15% +$2.06M ﹤0.01% 2219
2020
Q1
$11.6M Sell
709,806
-15,357
-2% -$317K ﹤0.01% 2192
2019
Q4
$14.9M Buy
725,163
+29,126
+4% +$485K ﹤0.01% 2324
2019
Q3
$7.99M Buy
696,037
+19,721
+3% +$225K ﹤0.01% 2576
2019
Q2
$8.89M Buy
676,316
+30,149
+5% +$403K ﹤0.01% 2563
2019
Q1
$9.78M Buy
646,167
+8,555
+1% +$137K ﹤0.01% 2480
2018
Q4
$10.9M Sell
637,612
-144,983
-19% -$2.48M ﹤0.01% 2384
2018
Q3
$11.5M Buy
782,595
+130,679
+20% +$2.32M ﹤0.01% 2501
2018
Q2
$15.6M Buy
651,916
+43,341
+7% +$1.07M ﹤0.01% 2306
2018
Q1
$15.6M Buy
608,575
+246,953
+68% +$5.88M ﹤0.01% 2217
2017
Q4
$6.68M Buy
361,622
+37,156
+11% +$532K ﹤0.01% 2655
2017
Q3
$3.4M Buy
324,466
+3,126
+1% +$34.5K ﹤0.01% 2970
2017
Q2
$4.03M Buy
321,340
+48,236
+18% +$477K ﹤0.01% 2846
2017
Q1
$2.75M Sell
273,104
-16,115
-6% -$240K ﹤0.01% 2970
2016
Q4
$4.53M Buy
289,219
+91,287
+46% +$1.52M ﹤0.01% 2749
2016
Q3
$3.81M Buy
197,932
+20,935
+12% +$249K ﹤0.01% 2714
2016
Q2
$2.1M Buy
176,997
+66,424
+60% +$1.1M ﹤0.01% 3011
2016
Q1
$2.01M Buy
110,573
+34,708
+46% +$631K ﹤0.01% 3003
2015
Q4
$2.09M Buy
75,865
+4,435
+6% +$93.4K ﹤0.01% 2979
2015
Q3
$1.58M Buy
71,430
+26,924
+60% +$487K ﹤0.01% 3082
2015
Q2
$794K Buy
+44,506
New +$770K ﹤0.01% 3294

Other funds holding COLL

State Street's COLL Position: Q1 2026 in Review

State Street increased its Collegium Pharmaceutical (COLL) stake by 8.7% in Q1 2026, buying an estimated $4.82M and bringing the position to 1,424,544 shares worth $47.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

State Street first reported a position in COLL in Q2 2015 and has held it in 44 quarters since. The position peaked at $60.7M in Q4 2025. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • State Street held 1,424,544 shares of Collegium Pharmaceutical worth $47.1M as of Q1 2026.
  • State Street bought 113,903 Collegium Pharmaceutical shares in Q1 2026, an estimated $4.82M.
  • Collegium Pharmaceutical made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1771 holding.
  • State Street first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 44 quarters since.
  • State Street's Collegium Pharmaceutical position peaked at $60.7M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.